ImPrecise Oversight? Cordis Monitoring Gaps Yield Second Warning Letter
This article was originally published in The Gray Sheet
Executive Summary
J&J Cordis says it is developing more "robust" systems and processes for overseeing clinical studies in response to FDA's warning letter faulting the company for sponsor monitoring lapses in its SAPPHIRE trial